Updated: Reimbursement Questions Jeopardize Hillrom/Bardy Merger
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
You may also be interested in...
Baxter’s management justified the deal by emphasizing the potential cost synergies and shared commitment to digital health innovation.
Media reports indicate Baxter is negotiating to acquire Hillrom for about $10bn, but the companies are not commenting on the reports.
The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.